Congress Slashes by 57% Program Funding Esophageal Cancer Research
As a shutdown deadline loomed, members of the US House and Senate voted to pass a budget plan crafted [...]
Learn About Inherited Gene Mutations & the Link to Esophageal Adenocarcinoma
Join us as Dr. Amitabh Chak and Dr. Kishore Guda of Case Western Reserve School of Medicine in Cleveland [...]
Major Insurer Provides Coverage for PreCancer Screening
A First Step for Lucid, perhaps a Giant Leap for Patients at Risk for Esophageal Cancer! In what could [...]
Art Journaling for Patients & Caregivers
ECAN is offering Esophageal Cancer Patients & Caregivers a special course in Art Journaling. Art journaling is a [...]
Learn about the Latest Therapy Approved by the FDA for Gastroesophageal Cancer Patients
A new type of therapy has been approved by the FDA for patients with Gastroesophageal Adenocarcinoma. Learn more. On [...]
More than 75% of Oncologists in some Communities are Not Ordering Biomarker Testing per Guidelines
Needed Biomarker Testing Not Happening for Patients with Advanced Gastroesophageal Cancer in Many Community Practices. In a Project with [...]
Find out about the Latest in Advancements for Esophageal Cancer Treatment
ECAN will host a free webinar on Tuesday, March 4, 2025 at 2:15 pm Eastern time to explore the [...]
FDA approves New Therapy Aimed at a New Target in Esophageal Cancer at the GE Junction
The Food and Drug Administration (FDA) has approved Zolbetuximab (Vyloy) as a first-line treatment for patients with advanced HER2* [...]
Study finds Regimen that doesn’t include Radiation is Better than current Standard
A German study finds a 30% reduction in the risk of death among Esophageal Adenocarcinoma patients who were treated [...]
FDA Advisory Panel votes to limit some EC patients’ access to immunotherapy
In 2021, Esophageal Cancer patients and advocates celebrated the Food and Drug Administration’s approval of immunotherapies for patients with [...]